Although non-small cell lung cancer (NSCLC) treatment shows unprecedented improvement with immune checkpoint inhibitors (ICIs), only a minority of NSCLC patients (25%) demonstrate long-term benefit. We hypothesize that therapeutic mRNA vaccination, coupled with co-targeting of antigen-presenting cell (APC) immunosuppressive functions, will sharply increase the number of patients who could benefit from ICIs.
Following the paradigm shift in vaccine development due to the COVID-19 pandemic, in which mRNA vaccines came to the forefront, we predict that these novel, cost-effective, flexible technologies will revolutionize personalized cancer care. Based on the complementary expertise of the consortium, we aim to obtain proof of concept (PoC) for a novel NSCLC mRNA vaccine, through the evaluation of an innovative mRNA + siRNA combination therapy to modulate APC toward restructure of the tumor microenvironment (TME).
For this, we will use our proprietary polymeric nanoparticles (NPs) to selectively deliver therapeutic nucleic acids to myeloid cells.